Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors

Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles, such as increased on-target off-tumor toxicities,...

Full description

Bibliographic Details
Main Authors: Jim Middelburg, Kristel Kemper, Patrick Engelberts, Aran F. Labrijn, Janine Schuurman, Thorbald van Hall
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
antibody therapy
immuno-oncology
CD3-bispecific antibody
T-cell engager
solid tumors
on-target off-tumor toxicity
Online Access:https://www.mdpi.com/2072-6694/13/2/287

Similar Items

Similar Items